Each year the Epilepsy Therapy Project in conjunction with the Epilepsy Foundation puts on a conference for new development in diagnostics, device and medication therapies emerging in the field of epilepsy. We summarize below a few of the presentations that we thought would be of interest to the JHN readership. For a full listing of the presentations please see http://www.epilepsy.com/ accelerating-new-therapies/2016-epilepsy-pipeline-conference.
In the new mechanism of action therapies there were three new products that were presented. Scotts Edwards updated the conference on progress of the compound SF0034 which a potent and selective KCNQ2/3 activator designed to suppress neuronal hyperexcitability in patients with partial-onset epilepsy. SF0034 was found to have significantly greater potency and selectivity in preclinical models of epilepsy compared with the known product ritagabine. Tansna President Mark Robbins, presented progress fir a new novel non-sedating agent derived from propofol which in early work had a favorable efficacy and side effect profile. Michael Ragowski presented on a new Inhaled treatment for refractory epilepsy, which is a prodrug of propofol, as a potential rescue for patients having seizures and want to try and avoid the oncoming seizure. Lastly and for a similar target, Jackie French presented data on Phase 2a for a status epileptic rescue medication that being developed by Alexza Pharmaceuticals for patients who have repetitive seizures and want to stop after the first seizure.
Abrams, MD, Daniel J.
"Epilepsy Pipeline Conference Summary,"
2, Article 6.
Available at: http://jdc.jefferson.edu/jhnj/vol11/iss2/6